Endocrine Abstracts

Aim: To evaluate the effect of risedronate vs ibandronate in treatment of systemic osteoporosis in postmenopausal women.

Materials and methods: We examined 57 postmenopausal women with systemic osteoporosis (average age 61±3.5 years). Bone mineral density (BMD) was determined by dual-energy X-ray absorptiometer (HOLOGIC Delphi W; SN 7044909) on lumbar spine. Examination was performed before the onset of treatment and after a period of 1, 2 and 3 years of treatment. Risedronate was taken in a dose of 35 mg weekly by 24 patients, while ibandronate 150 mg once a month by 33 patients. The women also received 1000 mg of calcium and 800 IU Vit D daily.

Results: After the first year of treatment, we observed an increase of 3.65% in BMD in risedronate group and a 4.7% in ibandronate group. The main difference came after 2 years of treatment, when, in the ibandronate group, we noticed a decrease in BMD by 4.25%, comparing with the other group (possible explanation – lack of compliance). In the third year there was an increase in both groups. No fractures were reported during this period.

Conclusion: Our experience shows that both risedronate and ibandronate are efficient against post-menopausal osteoporosis, with minimal side-effects.